Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Teoxane proposal to acquire Revance Therapeutics
We are advising Teoxane on the proposed acquisition
PL Developments exchange offer and consent solicitation
The exchange offer included the issuance of new PIK toggle senior secured notes due 2029
Owens & Minor $1.4 billion Rotech acquisition financing
We are advising the lead arrangers on the financing
Walgreens Boots Alliance $750 million notes offering
We advised Walgreens Boots Alliance on its debt offering
EyeCare Partners new refinancing transaction
We advised the superpriority, first-lien and second-lien administrative agent and the fronting bank on the transaction
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Greenway Health $375 million refinancing
We advised the administrative agent, arrangers and bookrunners on the financing
Auna $550 million secured term loan refinancing
We advised Auna on the transaction
Air Methods emerges from chapter 11
We advised the ad hoc group that negotiated and backstopped the restructuring